Abstract
Tumors contain viruses, bacteria, and fungi, collectively known as the microbiome. Here, experts discuss how the field evolved from reporting systemic effects of gut microbiota on the immune system, metastasis, and therapy response to studying intratumoral microbiome, and outline the future challenges and opportunities in modulating microbiota for therapeutic benefit.
| Original language | English |
|---|---|
| Pages (from-to) | 1443-1447 |
| Number of pages | 5 |
| Journal | Cancer Cell |
| Volume | 40 |
| Issue number | 12 |
| DOIs |
|
| Publication status | Published - 12 Dec 2022 |
Funding
Work related to the text by R.S. was funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 818086). G.D.S.-P. and R.K. wish to acknowledge the patients and their families who have helped contribute toward a better understanding of this field. R.K. is funded in part by grants from the National Cancer Institute (R01 CA255206 and U24 CA248454) and by the National Institutes of Health (NIH DP1AT010885).
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research